Assets
Bispecific Antibody Assets
Bispecific antibodies (BsAbs) are engineered antibodies capable of simultaneously binding to two different antigens or epitopes. Compared to monoclonal antibodies and combination therapies, BsAbs demonstrate higher efficacy, lower resistance, and a broader range of applicability due to new functional capabilities. They are expected to have lower toxicity than combined monoclonal antibody treatments. As a result, BsAbs are regarded as a new generation of antibody therapies.
-
10+
Fully-human BsAbs -
10+
TCR-mimic Assets
Why choose Biocytogen's BsAb portfolio?
- Produced by Biocytogen's proprietary RenLite® mice platform and generated by size unlimited chromosome engineering technology (SUPCE), it features a diversified heavy chain sequence repertoire similar to that of humans.
- RenLite-derived bsAbs have high binding affinity and high specificity.
- BsAbs span multiple areas including oncology, inflammation and autoimmunity.
- At Biocytogen, we adhere to the highest standards of quality and scientific rigor. Fully human bispecific antibodies have demonstrated excellent developability and efficacy through in vivo testing.
- We provide multiple collaboration models, including licensing, transfer, and co-development of bsAbs, and have established partnerships with numerous industry leaders. We warmly invite you to collaborate with us for the benefit of patients worldwide!
Our BsAb&Tri-Ab assets currently open for partnership
| Format | Therapeutic Area | Target(s) | Immunization |
|
Preclinical | IND | Phase I | Status |
| BsAb | Oncology | PD-1,CD40 |
|
Partnered | ||||
| BsAb | Oncology | OX40,CTLA4 |
|
|||||
| BsAb | Oncology | 4-1BB.CD40 |
|
|||||
| BsAb | Oncology | CD70,EGFR |
|
|||||
| BsAb | Oncology | CTLA4,TNFR2 |
|
|||||
| BsAb | Oncology | TIGIT,IL21 |
|
|||||
| BsAb | Infammation and Autoimmunity | 0X40 |
|
Exclusive MTA evaluation ongoing | ||||
| Tri-Ab | Oncology | DLL3.CD3E.4-1BB |
|
|||||
Selected assets overview
In addition, Biocytogen also has TCR-like antibody (TCRmimic) assets used for assembling bispecific antibodies with CD3. Contact us today to explore evaluation/licensing/co-development opportunities!
4-1BB x CD40 fully human bsAb (BCG021) for oncology
EGFR x CD70 fully human bsAb (BCG020) for oncology
CTLA-4 x OX40 fully human bsAb (YH006) for oncology
WT1 x CD3 fully human TCE for oncology
gp100 x CD3 fully human TCE for oncology
KRAS x CD3 fully human TCE for oncology
- Conditional 4-1BB and CD40 agonistic activity dependent on crosslinking of both targets
- Potent in vivo anti-tumor activity and significantly improved tumor growth inhibition when combined with anti-PD-1 mAb
- Desirable physicochemical properties
- Good in vivo safety in mice
- Antibody-like PK profile in mice
- Patent application has been submitted
- EGFR and CD70 parental antibodies demonstrated high affinity, high internalization activity, and blocking activity.
- EGFR x CD70 bsAb exhibited potent in vivo anti-tumor activity.
- Patent application has been submitted.
- MoA: Fc-dependent tumor-infiltrating Treg depletion.
- Superior preclinical anti-tumor activity compared to ipilimumab analog, other next-generation anti-CTLA-4 agents, and parental mAbs in the mouse model.
- Synergize with PD-1 or PD-L1 antibodies in mouse models.
- Good safety profile in mice.
- Excellent developability with upstream and downstream processes developed.
- Patent application has been submitted.
- High affinity and specificity against WT1/HLA-A02.
- Target-dependent and long-lasting T cell activation and proliferation.
- Dose-dependent anti-tumor efficacy.
- Minimal cytokine release in the absence of the target.
- gp100 is highly expressed in melanomas, weakly expressed in normal melanocytes and minimally expressed in non-melanocyte cells.
- Indications: melanoma.
- Our anti-gp100/HLA-A02 monoclonal antibodies from HLA-A02/RenMab mice have similar binding activity compared to the anti-gp100/HLA-A02 part of Tebentafusp-analog.
- Our gp100-311-TCE has same cytotoxic function as tebentafusp-analog in vitro.
- High affinity and specificity against KRAS G12V/HLA-A03.
- Excellent target-dependent binding properties.
- Dose-dependent tumor-lysis activity
- Targeting low antigen density effectively
